Ambu A/S: Ambu launches 4th generation of single-u
Post# of 301275
Innovation: 'Ambu ® aScope TM 4 Broncho' unveiled today in Vienna at European intensive care congress. Improved image quality means that Ambu expects new scope to be relevant for 50% more hospital procedures.
Over the course of the next three days, doctors and nurses can see and try the latest evolution of Ambu's single-use bronchoscope at the annual congress of the European Society of Intensive Care Medicine (ESICM). And they will experience that the new aScope is a technologically enhanced system with clearly better image quality and a new level of mechanical performance.
"We're proud to present the fourth generation of the aScope. It shows our ability to push the boundaries of high-tech single-use devices," says Ambu's CEO, Lars Marcher, "When we came out with the first version in 2009, we addressed a need to improve the workflow at hospitals and help doctors avoid exposing patients to device-related infections. This need is even more pressing today, as health care budgets are under pressure, and the aScope brings an empowered single-use endoscopy solution with economical and clinical benefits to the hospitals. The new aScope 4 Broncho will certainly expand the relevance of our solution."
Expands relevance by +50% Ambu expects aScope 4 Broncho to broaden the relevance of aScope by +50% - from a potential of approximately 3 million to a potential of 4-5 million annual procedures within pulmonary endoscopy worldwide - due to the technological advances of the solution. These advances include improved depth of field, improved adaptive light control, and increased sensitivity in the mechanical controls.
" From a development perspective, these latest advances are enablers on our way towards even more sophisticated single-use devices, " says Lars Marcher. " We have our eyes on the future of healthcare, and to us, relevance is the highest form of praise. "
Europe and Asia now, USA in 2018 aScope 4 Broncho has been developed in collaboration with bronchoscopy experts from across Europe and is now released for sale in Europe, Australia and selected markets in Asia. Ambu expects to have market clearance for sales in the US by early 2018.
Ambu's booth at the ESICM congress in Vienna is open for all interested health care professionals as of Monday morning 25 September 2017.
Ambu will comment on the financial impact of the launch of aScope 4 Broncho in connection with the company's Capital Market Day on 4 October 2017.
Contact and further information
Lars Marcher, President & CEO Phone +45 5136 2490. E-mail: lm@ambu.com
Read more online Go to www.ambu.com/ascope4broncho to read more about Ambu ® aScope TM 4 Broncho.
Attachments:
(0)
(0)